More than 44% of lung cancer patients were still alive after receiving the Tedopi therapeutic vaccine.
- Administration of the therapeutic vaccine Tedopi was shown to be effective in a phase 3 clinical trial in patients with advanced lung cancer.
- This vaccine instead of chemotherapy helps maintain a better quality of life for patients, according to those responsible for the study.
- The results of this clinical trial are a major advance for patients.
On Monday, September 11, Ose Immunotherapeutics, a French biotechnology company, revealed encouraging results regarding the development of its therapeutic vaccine Tedopi. The phase 3 clinical trial was carried out in patients with advanced lung cancer. This work was published in the journal Annals of Oncology.
Tedopi vaccine: a 41% reduction in the risk of death
For the purposes of this research, 219 patients were recruited in nine European countries and the United States. Some participants received the Tedopi vaccine while others received chemotherapy.
During the study, researchers found that administration of Tedopi serum was associated with a 41% reduction in the risk of death. One year after the start of treatments, 44.4% of volunteers who received the vaccine were still alive compared to 27.5% of patients who underwent chemotherapy. “Better quality of life” was also observed in participants who received the vaccine.
A type of patient targeted for vaccine administration
“Tedopi® is the first cancer vaccine to show positive results on survival in a randomized phase 3 trial, as a third-line treatment in patients with NSCLC [ndlr cancer du poumon non à petites cellules ] advanced or metastatic (…) The continuation of the evaluation of Tedopi® is fully justified in second line treatment of advanced or metastatic NSCLC in order to be able to offer this vaccine against cancer to difficult-to-treat failing patients, whose medical needs are important”indicated Professor Benjamin Besse, Director of Clinical Research at Gustave Roussy in a press release from Ose Immunotherapeutics.
For Nicolas Poirier, the general director of Ose Immunotherapeutics, these results constitute a major advance for the patients involved in the study and allow “to envision a new hope”. The findings of this research also clarified that people with “initially responded to immunotherapy before relapsing” are the most likely to receive the vaccine if it were to be marketed.
